TNF and endothelial dysfunction: Another target for cytokine modulation is TNF-α, and anti-TNF-α agents, such as infliximab, are currently being explored as therapies for TBI, particularly for their ability to ameliorate endothelial dysfunction in the setting of TBI (139, 140).